Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ACAD
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 3,321 | $20.88 | $69.3K Sale | Form 4 ↗ |
| Aug 6, 2026 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 9,292 | $29.34 | $272.6K Sale | Form 4 ↗ |
| Aug 6, 2026 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 5,000 | $29.00 | $145.0K Sale | Form 4 ↗ |
| Aug 5, 2026 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 5,849 | $29.00 | $169.6K Sale | Form 4 ↗ |
| Jul 30, 2026 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | ACAD ACADIA Pharmaceuticals Inc. | Sale | 50 | $26.17 | $1,309 Sale | Form 4 ↗ |
| Jul 30, 2026 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | ACAD ACADIA Pharmaceuticals Inc. | Sale | 16,508 | $26.13 | $431.4K Sale | Form 4 ↗ |
| Jun 26, 2026 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 11,421 | $26.08 | $297.9K Sale | Form 4 ↗ |
| May 26, 2026 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 5,401 | $21.18 | $114.4K Sale | Form 4 ↗ |
| May 4, 2026 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 3,506 | $21.79 | $76.4K Sale | Form 4 ↗ |
| May 4, 2026 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 1,332 | $21.79 | $29.0K Sale | Form 4 ↗ |
| Apr 7, 2026 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 2,709 | $22.20 | $60.1K Sale | Form 4 ↗ |
| Apr 7, 2026 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 1,030 | $22.20 | $22.9K Sale | Form 4 ↗ |
| Mar 26, 2026 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 37 | $21.72 | $804 Sale | Form 4 ↗ |
| Mar 26, 2026 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 3,171 | $21.65 | $68.7K Sale | Form 4 ↗ |
| Mar 26, 2026 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 12 | $21.73 | $261 Sale | Form 4 ↗ |
| Mar 26, 2026 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 1,097 | $21.65 | $23.8K Sale | Form 4 ↗ |
| Mar 25, 2026 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 4,177 | $21.47 | $89.7K Sale | Form 4 ↗ |
| Mar 25, 2026 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | ACAD ACADIA Pharmaceuticals Inc. | Sale | 3,435 | $21.47 | $73.7K Sale | Form 4 ↗ |
| Mar 25, 2026 | Adams Catherine Owen Chief Executive Officer, Director | ACAD ACADIA Pharmaceuticals Inc. | Sale | 11,641 | $21.47 | $249.9K Sale | Form 4 ↗ |
| Mar 25, 2026 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 833 | $21.47 | $17.9K Sale | Form 4 ↗ |
| Mar 25, 2026 | Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | ACAD ACADIA Pharmaceuticals Inc. | Sale | 3,844 | $21.47 | $82.5K Sale | Form 4 ↗ |
| Feb 9, 2026 | Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | ACAD ACADIA Pharmaceuticals Inc. | Sale | 6,950 | $23.38 | $162.5K Sale | Form 4 ↗ |
| Nov 18, 2025 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 10,262 | $23.69 | $243.1K Sale | Form 4 ↗ |
| Nov 18, 2025 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 4,084 | $23.69 | $96.7K Sale | Form 4 ↗ |
| Nov 10, 2025 | James M. Daly Director | ACAD ACADIA Pharmaceuticals Inc. | Sale | 30,000 | $22.37 | $671.1K Sale | Form 4 ↗ |
| Sep 15, 2025 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 3,498 | $23.65 | $82.7K Sale | Form 4 ↗ |
| Sep 2, 2025 | Elizabeth A. Garofalo Director | ACAD ACADIA Pharmaceuticals Inc. | Sale | 1,600 | $25.98 | $41.6K Sale | Form 4 ↗ |
| Aug 18, 2025 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 22,000 | $25.18 | $554.0K Sale | Form 4 ↗ |
| Jun 4, 2025 | Laura Brege Director | ACAD ACADIA Pharmaceuticals Inc. | Sale | 14,446 | $21.78 | $314.6K Sale | Form 4 ↗ |
| May 16, 2025 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 2,000 | $20.00 | $40.0K Sale | Form 4 ↗ |
| May 16, 2025 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 2,000 | $25.00 | $50.0K Sale | Form 4 ↗ |
| May 16, 2025 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 2,000 | $25.00 | $50.0K Sale | Form 4 ↗ |
| May 2, 2025 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 1,327 | $14.60 | $19.4K Sale | Form 4 ↗ |
| May 2, 2025 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 3,498 | $14.60 | $51.1K Sale | Form 4 ↗ |
| Apr 8, 2025 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 2,708 | $14.82 | $40.1K Sale | Form 4 ↗ |
| Apr 8, 2025 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 1,028 | $14.82 | $15.2K Sale | Form 4 ↗ |
| Mar 26, 2025 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 1,095 | $17.05 | $18.7K Sale | Form 4 ↗ |
| Mar 26, 2025 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 3,171 | $17.05 | $54.1K Sale | Form 4 ↗ |
| Mar 5, 2025 | Elizabeth A. Garofalo Director | ACAD ACADIA Pharmaceuticals Inc. | Sale | 4,919 | $18.23 | $89.7K Sale | Form 4 ↗ |
| Feb 24, 2025 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 475 | $19.96 | $9,481 Sale | Form 4 ↗ |
| Feb 24, 2025 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 773 | $19.96 | $15.4K Sale | Form 4 ↗ |
| Nov 19, 2024 | Brendan Teehan EVP, COO, HEAD OF COMMERCIAL | ACAD ACADIA Pharmaceuticals Inc. | Sale | 10,329 | $16.81 | $173.6K Sale | Form 4 ↗ |
| Nov 19, 2024 | James Kihara PRINCIPAL ACCOUNTING OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 4,073 | $16.81 | $68.5K Sale | Form 4 ↗ |
| Nov 19, 2024 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | ACAD ACADIA Pharmaceuticals Inc. | Sale | 10,259 | $16.81 | $172.5K Sale | Form 4 ↗ |
44 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:19 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances